February 3rd, 2026TGA issues infringement notices overweight loss medicine ads
The TGA has issued infringement notices to Prime Medic Group and an individual for the alleged unlawful advertising of weight loss medicines, in contravention of the Therapeutic Goods Act 1989 (the Act).
One infringement notice for $19,800 was issued to Prime Medic, and one for $3,960 was issued to an individual. Prime Medic and the individual paid the infringement notices in January 2026.
Allegations relating to advertising of prescription-only medicines
Prime Medic operates an online telehealth platform offering consultations with doctors. It is alleged that Prime Medic advertised prescription-only weight loss medicines, including Ozempic and Mounjaro, directly to consumers between at least January and July 2025.
Under the Act, advertising prescription-only medicines to the public is prohibited. These restrictions exist to help prevent inappropriate demand for prescription treatments and to support safe use under clinical supervision.
Decisions about whether a prescription treatment is appropriate should be made by a patient in consultation with a qualified health professional, based on individual clinical circumstances.
Allegations relating to restricted or prohibited representations
It is also alleged that the advertising promoted the use of therapeutic goods for the treatment of serious diseases, conditions or disorders.
References of this kind are known as restricted or prohibited representations and must not be included in advertising for therapeutic goods unless approval or permission is granted by the TGA.
Reminder to health providers and advertisers
Health providers, advertisers, and publishers are reminded that they must understand and comply with their legal obligations before advertising therapeutic goods. This includes ensuring:
- prescription-only medicines are not promoted directly to consumers
- advertising does not include restricted or prohibited representations without the required approvals
- marketing content does not create inappropriate expectations about treatment access or suitability
The TGA encourages a risk-based approach to advertising compliance, including ensuring all material is reviewed before publication
